secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-07-13T23:59:59+00:00
Accession:  0001607062-21-000210
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts
--------------------------------------------------------------------------------

- Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).
- Notice of allowance received for antigen-specific mRNA cancer vaccine (app. 15/162,370).
- Two patent assets in revival: siRNA cancer therapy (8,389,708) and universal donor cord blood killer cells (15/494,358).
- Active applications include NR2F6 inhibition combined with cannabidiol for cancer, angiogenesis, arthritis; small molecule NR2F6 modulators.
- Zander Therapeutics licensed patent for canine dendritic cell immunotherapy (10,030,227).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/0001607062-21-000210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000210/rgbp071321form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer